Schisandrin B suppresses cholangiocarcinoma by targeting the ROS/p38 MAPK/NF-κB axis.

Oncol Lett · 2026 · PMC13051282 · PMID 41947899

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Additionally, western blot analysis indicated a decreasing trend in p-p38 expression with higher Sch B concentrations, further demonstrating inhibition of the MAPK signaling pathway ( Fig. 5C ).

also in 47,180 other papers

an increasing trendno p-value reported

The results showed an increasing trend, indicative of a dose-dependent effect ( Fig. 3A-C ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.